Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy

Yue Li1,2,3, Long Zhao1,3 and Xiao-Feng Li1,3*

1 Department of Nuclear Medicine, The Second Clinical Medical College, Jinan University (Shenzhen People’s Hospital), Shenzhen, China, 2 The First Affiliated Hospital, Jinan University, Guangzhou, China, 3 Department of Nuclear Medicine, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China

Hypoxia is an important characteristic of most solid malignancies, and is closely related to tumor prognosis and therapeutic resistance. Hypoxia is one of the most important factors associated with resistance to conventional radiotherapy and chemotherapy. Therapies targeting tumor hypoxia have attracted considerable attention. Hypoxia-activated prodrugs (HAPs) are bioreductive drugs that are selectively activated under hypoxic conditions and that can accurately target the hypoxic regions of solid tumors. Both single-agent and combined use with other drugs have shown promising antitumor effects. In this review, we discuss the mechanism of action and the current preclinical and clinical progress of several of the most widely used HAPs, summarize their existing problems and shortcomings, and discuss future research prospects.

Keywords: hypoxia, hypoxia-activated prodrugs, tirapazamine, AQ4N, PR-104, EO9, TH-302, SN30000

INTRODUCTION

Hypoxia is a hallmark of a wide variety of solid tumors. In tumors, hypoxia arises due to a mismatch between oxygen delivery and consumption. Hypoxia is closely related to tumor progression, metastasis, therapeutic resistance, and poor prognosis (1). Hypoxia in tumor microenvironment leads to the transcriptional induction of a series of genes. The most important factor mediating this response is the hypoxia-inducible factor-1 (HIF-1), which extensively participates in glucose metabolism, angiogenesis, apoptosis, tumor metastasis and therapeutic resistance (2). Under hypoxic condition, HIF-1α regulates the switch from oxidative phosphorylation to anaerobic glycolysis, by activating the expression of glucose transporter 1 and 3 (GLUT-1 and GLUT-3) and related glycolytic enzymes (3). By regulating its downstream angiogenesis related genes, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), matrix metalloproteinases (MMPs), HIF-1α is widely involved in every step of angiogenesis, including endothelial progenitor cells recruitment and their differentiation to endothelial cells and smooth muscle cells, degradation of extracellular matrix, and the stability of peripheral cells (4). HIF-1α could induce apoptosis by regulating p53, Bcl-2, BNIP-3 and other genes (5). Through induction of MMPs, E-cadherin, CXCR4, CA9, HIF could promote tumor invasion and metastasis by regulating epithelial-to-mesenchymal transition (EMT) (6).

Tumor cells response to hypoxia depends in part on the duration of exposure. Hypoxic tumor cells may undergo necrosis, but some of the tumor cells may adjust to hypoxic stress and survive, which is also mediated by HIF-1α, resulting in a more aggressive phenotype and therapeutic resistance (5). Hypoxia and HIF could induce cell cycle arrest and hypoxic tumor cells generally
have a relatively low proliferation rate (7, 8), while radiotherapy or chemotherapy mainly act on proliferating cells (9–11). Therefore, the hypoxic regions of tumors are usually insensitive to current radiotherapy and chemotherapy, and treatments targeting the hypoxic regions may provide additional clinical benefits. To this end, increasing efforts have been focused on the development of agents that selectively target and kill hypoxic tumor cells.

Hypoxia-activated prodrugs (HAPs), also referred to as bioreductive drugs, are compounds that can be selectively reduced by specific reductases under hypoxic conditions to form cytotoxic agents that precisely target hypoxic tumor cells and have little toxicity to normal tissue. At present, several classes of HAPs have been developed, including quinones, nitroaromatics, aliphatic N-oxides and hetero-aromatic N-oxides. The most representative ones are tirapazamine, AQ4N (banoxantrone), PR-104, EO9 (apaziquone), TH-302 (evofosfamide), and SN30000 (Figure 1). This review puts a special emphasis on the past achievements as well as limitations of HAPs and attempts to analyze the potential reasons for unsuccessful clinical trials, with the aim of guiding future investigations into optimizing the use of this therapeutic approach.

**TIRAPAZAMINE**

Tirapazamine (SR-4233, WIN 59075) [3-amino-1,2,4-benzotriazine-1,4 dioxide], the first hypoxia-activated prodrug, was reported in 1986 (12). Through one-electron reduction, the prodrug can generate an oxidative radical, which will diffuse into hypoxic regions and cause oxidative damage (13) (Figure 2). Cytochrome P-450 (CYP) is the main catalytic reductase involved in the reduction of tirapazamine (14). Although evidence showed that tirapazamine is a substrate for NAD(P)H: (quinone acceptor) oxidoreductase (DT-diaphorase) (15), the amount of DT-diaphorase expression in cells did not affect their sensitivity to tirapazamine (16).

Tirapazamine kills hypoxic cells by inducing chromosome aberrations and DNA double-strand breaks (17). Chromosome breaks caused by tirapazamine were more damaging and difficult to repair (18). Under hypoxic conditions, tirapazamine causes damage to both purine and pyrimidine residues in double-stranded DNA. DNA base damage was dominated by formation of formamidopyrimidine and 5-hydroxy-6-hydropyrimidine (19, 20). The DNA damaging activity of tirapazamine mainly results from radicals generated within the nucleus but not in the cytoplasm (21). Tirapazamine can induce acute changes in energy metabolism and intracellular pH in tumors (22). Skarsgard et al. (23) found that tirapazamine-induced DNA damage was pH-dependent (more effective at acidic pH) and could be repaired by certain gene products including uvrC and exonuclease III (24). The affinity of tirapazamine for hypoxic tissues was confirmed by many researchers but Durand and Olive demonstrated that this selectivity of tirapazamine was much lower in vivo (3 fold higher than aerobic) than that observed in vitro (50-500 fold) (25). Under aerobic conditions, tirapazamine can still induce cell cycle interruption and apoptosis, which may lead to its aerobic toxicity (26).

In preclinical studies, tirapazamine effectively inhibited tumor colony-forming in vitro, especially in hypoxic cells (27). Tirapazamine induced cell cycle arrest and apoptosis, and down-regulated HIF-1α, CA-IX and VEGF expression (28, 29). Brown (30) suggested that the activity of tirapazamine was p53-independent, but Yang’s study on neuroblastoma revealed that tirapazamine had clinical activity only in p53-functional neuroblastoma (31). Zeman and Brown published a series of reports focusing on the radiosensitization effects of tirapazamine. They reported that tirapazamine enhanced radiation-induced
antineoplastic effects while sparing normal tissues (12, 32–38). As flavone acetic acid (FAA) reduces the blood supply of tumors, tirapazamine in combination with FAA could significantly enhance the antineoplastic efficacy of both drugs (39). Many studies have investigated the synergistic effect of tirapazamine and chemotherapy (such as cyclophosphamide, cisplatin, paclitaxel, etc.) or radioimmunotherapy (40–45). Tirapazamine, together with hyperthermia, electric pulses, etc. also exhibited encouraging antineoplastic efficacy (46–49). However, studies conducted by Adam et al. (50, 51) demonstrated that tirapazamine plus cisplatin and/or irradiation significantly increased toxicity and mortality.

In clinical trials, the reported adverse events associated with tirapazamine included muscle cramping, ototoxicity, granulocytopenia, nausea and vomiting, etc. (52, 53). Most phase 1 and 2 clinical trials have shown encouraging antineoplastic efficacy and tolerable toxicity (54–60). However, others, as well as two phase 3 clinical studies showed little benefit or significant toxicity (61–65).

AQ4N

AQ4N [1,4-bis[2-(dimethylamino-N-oxide)ethyl]amino]-5,8-dihydroxyanthracene-9,10-dione], an aliphatic N-oxide, was first reported in 1993 (66). Its prodrug has no intrinsic DNA binding affinity and thus is non-toxic. Under hypoxic conditions, AQ4N can be activated into AQ4 (with an intermediate product AQ4M) through a two-electron reduction mediated by CYP, which is DNA-affinic and possesses 1000-fold cytotoxic potency compared with its prodrug (Figure 3). During the subsequent decade, Patterson and his team deeply investigated the pharmacology of AQ4N. They demonstrated that AQ4N combined with radiotherapy or chemotherapy (cisplatin, cyclophosphamide, thiotepa, mitoxantrone) showed enhanced antineoplastic effects (67–70). In 2003, they proposed a gene-directed enzyme prodrug therapy (GDEPT) strategy using CYPs in order to facilitate the bioreduction of AQ4N (71). Other researchers also investigated the activation of AQ4N by different types of CYPs and nitric oxide synthase (NOS) (72–75).

Many researchers have confirmed that AQ4N exerts antitumor effects in preclinical models of pancreatic cancer (76), bladder cancer and lung cancer (77), prostate cancer (78), gliosarcoma (79), etc., in both single-agent and combined chemotherapy, and in radiotherapy. Gieling et al. (80) demonstrated that AQ4N was more effective toward metastases in a fibrosarcoma-bearing mouse model (subcutaneous KHT tumors). Trédan et al. compared the penetration capacity of AQ4N and mitoxantrone through multi-layer cell cultures and
tumor xenografts, and found that AQ4N could penetrate deeply into the hypoxic regions of the tumor and that combination therapy of AQ4N with mitoxantrone showed decreased tumor growth (81). There is also evidence showed that AQ4N had anti-angiogenic effects (82, 83).

The first phase 1 study of AQ4N was reported in 2007, in which 22 esophageal carcinoma patients received an AQ4N infusion followed by fractionated radiotherapy (84). Three of 22 patients had > 50% reductions in tumor volume and 9 had stable disease without dose-limiting toxicity. Albertella et al. enrolled 32 patients with different malignancies in a phase 1 study, and demonstrated that AQ4N was activated selectively in hypoxic regions of tumors and that it can penetrate the blood-brain barrier (85). No objective antitumor effect was observed in another phase 1 clinical study conducted by Papadopoulos et al. (86).

In recent years, a series of new therapeutic strategies have been under development, including combination therapy with AQ4N and photodynamic therapy (PDT), vascular-targeted photodynamic therapy (VTP) (87–92). Feng et al. (93) developed a treatment strategy that combined PDT with AQ4N. Using an AQ4N-64Cu-hCe6-liposome in vivo PET probe, they were able to monitor tumor hypoxia status after illumination with light-emitting diode light and demonstrated that utilization of PDT-induced hypoxia to trigger hypoxia-targeted therapy achieved significant antineoplastic effects. Zhang et al. (94) showed that AQ4N combined with starvation therapy (by using stealth liposomes to deliver glucose oxidase together with prodrugs) exhibited similar enhancement of antitumor effects. These methodologies provide new insights for future cancer diagnosis and therapy.

**PR-104**

PR-104 is a 3,5-dinitrobenzamide-2-mustard. The water-soluble phosphate PR-104 can transform to a more lipophilic prodrug PR-104A (3,5-dinitrobenzamide-2-nitrogen mustard) systemically, and then, under hypoxic conditions, it can be further activated by reduction to PR-104H (5-hydroxylamine) and PR-104M (5-amine), allowing it to act as a DNA interstrand cross-linking agent in hypoxic cells and exert cytotoxic effects (95) (Figure 4). The reduction reaction is catalyzed anaerobically mainly by NADPH-cytochrome P450 reductase (96). There are studies demonstrating that PR-104 may also be reduced by aldo-keto reductase (AKR) 1C3 anaerobically, which might cause systemic toxicity (97, 98). The sensitivity of PR-104 depends on the oxygenation status, reductase activity, and DNA repair ability (99). Two studies have revealed the bystander effect of PR-104 (100, 101).

In *in vitro* studies, the antitumor efficacy of PR-104 has been investigated in cervical squamous cell carcinoma (SiHa cells), ovarian carcinoma (A2780 cells), non-small cell lung carcinoma (H1299 and A549 cells), colorectal carcinoma (RKO and HCT116 cells), hepatocellular carcinoma, etc., PR-104 as a single agent or in combination with radiotherapy or chemotherapy has shown different degrees of antineoplastic effects (95, 102–104).

In clinical trials, however, no or only partial responses were observed, but with obvious toxicities, mainly thrombocytopenia and neutropenia (105–108). However, PR-104 showed advantages in the treatment of leukemia. Evidence showed that in acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, and acute myeloid leukemia, PR-104 decreased...
tumor burden and prolonged survival in pre-clinical studies (109), and also was associated with disease response in a phase I/II clinical trial (110). The expression of AKR1C3 can be used as a biomarker to predict response to PR-104 and patients screening (111).

EO9 (APAZIQUONE)

EO9 (Apaziquone) [3-hydroxy-5-aziridinyl-1-methyl-2(1H-indole-4,7-dione)prop-beta-en-alpha-ol], which is structurally related to mitomycin C, was first reported in 1989 and has been deeply investigated since then. Pharmacological studies have shown that DT-diaphorase plays a vital role in the reduction of EO9 prodrug (112), implying that detection of DT-diaphorase activity might predict the sensitivity of certain tumors to EO9 (113–115) (Figure 5).

In vitro, EO9 was proved effective toward colon adenocarcinoma cells, melanoma cells, central nervous system tumors, renal cancer cells, oral squamous cell carcinoma, and lung cancer cells (including NSCLC and certain cell lines of small cell lung cancer). In vivo, gastric and colorectal adenocarcinoma, ovarian carcinoma, and breast carcinoma were sensitive while leukemia was found to be resistant to EO9 (116–118). Certain inducers such as 1,2-dithiole-3-thiones (D3T) could enhance DT-diaphorase activity, thereby increasing the sensitivity of EO9 (119, 120). However, some researchers pointed out that in vitro studies on DT-diaphorase activity are different from in vivo studies, and may result in different sensitivity measurements (121). Further pharmacological studies have shown that in the presence of oxygen, DT-diaphorase reduces EO9 through 2-electron reduction, and the product is hydroquinone; while under hypoxic conditions, EO9 undergoes 1-electron reduction, and the product is semiquinone, which is more toxic than hydroquinone (122, 123). Therefore, EO9 may be more effective for hypoxic solid tumors (124, 125). Studies have also shown that the anti-tumor effect of EO9 is pH-dependent, and may exert a tumor suppressor effect in tumor areas with low pH (pH5.5–7.0) (126).

For clinical trials, nephrotoxicity and proteinuria were observed in both phase 1 and phase 2 clinical studies, but only partial response or stable disease was achieved (127–131). The reason for these unsatisfactory results may be attributed to the instability of both semiquinone and hydroquinone, with a short half-life and poor permeability, which will be quickly removed in vivo (131–134). However, this special pharmacokinetic profile is ideal for local treatment (135, 136). Intravesical instillation of EO9 was well tolerated and effective for superficial bladder cancer, manifested by a higher complete remission rate and a lower recurrence rate (137–139). A recent study pointed out that EO9 may be inactivated by hematuria, which suggests that the timing of medication should be selected with this in mind in the design of future phase 3 clinical trials (140).

TH-302 (EVOFOSFAMIDE)

TH-302 (Evofosfamide), a second-generation HAP, consists of a 2-nitroimidazole moiety linked to bromo-iso-phosphoramide mustard (Br-IPM). Br-IPM is a DNA cross-linking agent. Under hypoxic conditions through a 2-nitroimidazole reduction reaction, TH-302 prodrug releases Br-IPM and perform cytotoxic effect (141) (Figure 6). Cytochrome P450 oxidoreductase (POR) also plays an important role in the reduction reaction and is the main determinant of cell sensitivity to TH-302 (142). Thus, the efficacy of TH-302 is highly dependent on the tumor type (143).

Many researchers have reported the antitumor efficacy of TH-302 as a single agent in malignancies including multiple myeloma, osteosarcoma, chondrosarcoma, neuroblastoma, rhabdomyosarcoma, breast cancer, non-small cell lung cancer, head and neck tumors, acute myeloid leukemia, etc. (144–152). The effect of TH-302 on spherical cells was significantly enhanced (153) and its activity was related to tumor hypoxic fractions (154), indicating that TH-302 had high hypoxic selectivity. The reported antineoplastic mechanisms include DNA fragmentation, cell cycle arrest, down-regulation of hypoxia-inducible factor-1α expression, etc.

In addition to monotherapy, TH-302 also showed synergistic effects with many traditional chemotherapy drugs, including doxorubicin, topotecan, paclitaxel, cisplatin, docetaxel, pemetrexed, irinotecan, gemcitabine, and temozolomide (155–157). TH-302 was able to inhibit the reoxygenation and
proliferation of hypoxic tumor cells that survived chemotherapy (158). Studies also revealed that the application of hypoxia inducers, such as Chk1 inhibitor, mTOR inhibitor, hydralazine, and pyruvate, enhanced the efficacy of TH-302 (159–161). TH-302 also has a radiosensitization effect. It exerts a synergistic effect when combined with radiotherapy (162–164). TH-302 has been shown to be beneficial in combination with conventional transarterial chemoembolization (cTACE) (165); anti-angiogenic therapy, such as VEGF-A inhibitor, sunitinib, and pazopanib (166–168); molecular targeted therapy, such as sorafenib and erlotinib (169, 170); and immunotherapy, such as CTLA-4 and PD-1 blockade (171, 172), where it also exerted a significant tumor inhibition effect.

Recent evidence suggests that TH-302 can not only kill hypoxic pancreatic cancer cells, but also has the ability to improve the oxygenation status of residual tumor cells, so it may be useful to enhance the effect of radiotherapy and chemotherapy (173).

Since 2007, TH-302 has been in clinical trials. The main toxicities reported were skin and/or mucosal toxicity, thrombocytopenia, neutropenia, and myelosuppression (174–177). Several phase 1/2 clinical trials have reported encouraging results. For several types of tumors, including soft tissue sarcoma, pancreatic cancer, glioblastoma, and papillomavirus-negative head and neck squamous cell carcinoma, etc, TH-302 alone or in combination with other therapies showed varying degrees of antineoplastic activity (171, 175–178). It showed limited efficacy in the treatment of leukemia and failed in two phase 3 clinical trials (179–181). Researchers analyzed the possible reasons, including the lack of patient screening based on tumor hypoxia status (182, 183), antagonism between drugs (184), and drug formulation changes (185). Further research is still in progress.

**SN30000**

SN30000 [3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno[5,6-e]1,2,4-triazine 1,4-dioxide], previously known as CEN-209, is a second-generation benzotriazine-N-oxide hypoxia-activated prodrug and a modified analogue of tirapazamine (Figure 7). Currently, it is still in the stage of preclinical research. Several studies have confirmed that SN30000 possesses similar pharmacological mechanisms (186) to tirapazamine, but is superior in terms of antineoplastic effects and hypoxia selectivity (187).

Mao et al. (188) proved that, compared with monolayer tumor cells, SN30000 has higher activity on tumor spheroids, and when combined with radiation, it can cause significant tumor spheroid growth delay. Moreover, when used together with or before gemcitabine, SN30000 can effectively inhibit the proliferation of reoxygenated tumor cells (189). EF5 binding may be a promising biomarker for hypoxia stratification and SN30000 treatment response assessment (190, 191).


CONCLUSIONS AND SUGGESTIONS FOR FUTURE INVESTIGATIONS

Since the 1980s, HAPs have been developed and validated step by step, from preclinical to clinical. Despite their antineoplastic effects, their drawbacks and limitations have also been revealed by many studies. Here, we summarize the past experience and the latest research progress, and propose the following directions for future research (Table 1):

First, screening methods need to be developed based on tumor hypoxia to select the best candidates for this type of therapy. A growing number of studies have shown that PET/CT imaging can be an effective method to monitor HAPs uptake and therapeutic response (148, 190, 192). Second, biomarkers to predict drug sensitivity are needed. Since HAP is a bioreductive drug, it requires specific enzymes to complete the reduction reaction. Therefore, the detection of specific enzymes can play a role in predicting drug sensitivity (112, 142). In addition, experiments conducted by our group and others showed that hypoxic tumor cells could only survive for 2-3 days in vivo (193, 194), suggesting that hypoxic cells are destined to enter necrosis in vivo and that hypoxia-targeting therapy of macroscopic tumors should be revisited.

REFERENCES

1. Evans SM, Koch CJ. Prognostic Significance of Tumor Oxygenation in Humans. Cancer Lett (2003) 195(1):1–16. doi: 10.1016/s0304-3835(03)00012-0
2. Challapalli A, Carroll L, Abogaie EO. Molecular Mechanisms of Hypoxia in Cancer. Clin Transl Imaging (2017) 5(3):225–53. doi: 10.1007/s40336-017-0231-1
3. Bristow RG, Hill RP. Hypoxia and Metabolism. Hypoxia, DNA Repair and Genetic Instability. Nat Rev Cancer (2008) 8(3):180–92. doi: 10.1038/nrc2344
4. Carmellet P, Jain RK. Molecular Mechanisms and Clinical Applications of Angiogenesis. Nature (2011) 19473(7347):298–307. doi: 10.1038/nature10144
5. Lum JJ, Bui T, Gruber M, Jordan JD, DeBerardinis RJ, Covello KL, et al. The Transcription Factor HIF-1alpha Plays a Critical Role in the Growth Factor-Dependent Regulation of Both Aerobic and Anaerobic Glycolysis. Genes Dev (2007) 21(9):1037–49. doi: 10.1101/gad.1529107
6. Joseph JP, Harishankar MX, Pillai AA, Devi A. Hypoxia Induced EMT: A Review on the Mechanism of Tumor Progression and Metastasis in OSCC, Oral Oncol (2018) 80:23–32. doi: 10.1016/j.oraloncology.2018.03.004
7. Li XF, Carlin S, Urano M, Russell J, Ling CC, O’Donoghue JA. Visualization of Hypoxia in Microscopic Tumors by Immunofluorescent Microscopy. Cancer Res (2007) 67(16):7646–53. doi: 10.1185/00085472.CAN-06-4353
8. Li XF, O’Donoghue JA. Hypoxia in Microscopic Tumors. Cancer Lett (2008) 264(2):172–80. doi: 10.1016/j.canlet.2008.02.037
9. Horsman MR, Overgaard J. The Impact of Hypoxia and Its Modification of the Outcome of Radiotherapy. J Radiat Res (2016) 57(suppl 1):i90–i98. doi: 10.1093/jrr/rsw007
10. Manoochehr Khoshinani H, Afshar S, Najafi R. Hypoxia: A Double-Edged Sword in Cancer Therapy. Cancer Invest (2016) 34(10):536–45. doi: 10.1080/07357907.2016.1245317
11. Kim JY, Lee JY. Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How it Can be Overcome. Int J Mol Sci (2017) 18(9):1854. doi: 10.3390/ijms18091854
12. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW, Sr-4233: A New Bioreductive Agent With High Selective Toxicity for Hypoxic Mammalian Cells. Int J Radiat Oncol Biol Phys (1986) 12(7):1239–42. doi: 10.1016/0360-3016(86)90267-1
13. Laderoute K, Wardman P, Rauth AM. Molecular Mechanisms for the Hypoxia-Dependent Activation of 3-Amino-1,2,4-Benzotriazine-1,4-Dioxide (Sr 4233). Biochim Pharmacol (1988) 37(8):1487–95. doi: 10.1016/0006-2952(88)90010-x
14. Saunders MP, Patterson AV, Chinje EC, Harris AL, Stratford IJ. NADPH: Cytochrome C (P450) Reductase Activates Tirapazamine (SR4233) to Restore Hypoxic and Oxic Cytotoxicity in an Aerobic Resistant Derivative
26. Lin PS, Ho KC, Yang SJ. Tirapazamine (SR 4233) Interrupts Cell Cycle

27. Hanauske AR, Ross M, Degen D, Hilsenbeck SG, Von Hoff DD.

21. Evans JW, Yudoh K, Delahoussaye YM, Brown JM. Tirapazamine Is

22. Aboagye EO, Dillehay LE, Bhujwalla ZM, Lee DJ. Hypoxic Cell Cytotoxin

17. Elwell JH, Siim BG, Evans JW, Brown JM. Adaptation of Human Tumor Cells to

31. Yang B, Reynolds CP. Tirapazamine Cytotoxicity for Neuroblastoma is p53

20. Birincioglu M, Jaruga P, Chowdhury G, Rodriguez H, Dizdaroglu M, Gates

15. Riley RJ, Workman P. Enzymology of the Reduction of the Potent

19. Clark W, Tacon F, Brown JM. The Therapeutic Usefulness of Combined Treatments With

13. Klein-Szanto AJ, The Enzymatic Reduction of the Potent Hypoxic Cell Cytotoxin

14. Frei E, Hoffman R. Targeting Hypoxia in Cancer: The Therapeutic Potential of

12. Pajak T, Cohen RB, Poppiti RJ, Brown JM, Schild SE. Fractionated Irradiation

11. Brown JM. Exploiting Tumor Hypoxia and Overcoming Mutant P53 With

30. Brown JM. Exploiting Tumor Hypoxia and Overcoming Mutant P53 With

29. Kelepouris E, Aboagye EO, Bhujwalla ZM, Reed TS, Lee DJ. Mitomycin C and

28. Aboagye EO, Kelepouris E, Bhujwalla ZM, Lee DJ, Price MD. Bioreductive

27. Tucker GS, Brown JM. The Enzymology and Therapeutic Potential of

26. Brigdale FS, Houseknecht KD, Dumanian GA, et al. A Combination of

25. Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combined Bioreductive Drugs (SR 4233 or SN 23862) With the Vasoactive Agents Flavone Acetic Acid or 5,6-Dimethylanthanenone Acetic Acid. Int J Radiat Oncol Biol Phys (1994) 29(2):373–7. doi: 10.1016/0360-3016(94)90292-5

24. Masunaga S, Ono K, Hori, Shibata T, Suzuki M, Kinashi Y, et al. Effect of Bioreductive Agents, Tirapazamine and Mitomycin C, on Quiescent Cell Populations in Solid Tumors, Evaluated by Micronucleus Assay. Int J Cancer Res (1997) 88(9):907–14. doi: 10.100111.1349-7006.1997.b100468.x

23. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining Bioreductive Drugs (SR 4233 or SN 23862) With the Vasoactive Agents Flavone Acetic Acid or 5,6-Dimethylanthanenone Acetic Acid. Int J Radiat Oncol Biol Phys (1994) 29(2):373–7. doi: 10.1016/0360-3016(94)90292-5

22. Masunaga S, Ono K, Hori, Shibata T, Suzuki M, Kinashi Y, et al. Effect of Bioreductive Agents, Tirapazamine and Mitomycin C, on Quiescent Cell Populations in Solid Tumors, Evaluated by Micronucleus Assay. Int J Cancer Res (1997) 88(9):907–14. doi: 10.100111.1349-7006.1997.b100468.x

21. Weitman S, Mangold G, Marty J, Dexter D, Hilsenbeck S, Rake J, et al. Evidence of Enhanced In Vivo Activity Using Tirapazamine With Paclitaxel and Paraplatin Regimens Against the MV-522 Human Lung Cancer Xenograft. Cancer Chemother Pharmacol (1999) 43(5):402–8. doi: 10.1007/s002800050914

20. Jounaidi Y, Wadman DJ. Combination of the Bioreductive Drug Tirapazamine With the Chemotherapeutic Prodrug Cyclophosphamide for P450/P450-Reductase-Based Cancer Gene Therapy. Cancer Res (2000) 60(14):5761–9. doi: 10.1016/1469-8090(99)01214-4

19. Masunaga S, Ono K, Hori, Shibata T, Suzuki M, Kinashi Y, Takagaki Y, et al. Change in Oxygenation Status in Tumor Total and Quiescent Cells Following Gamma-Ray Irradiation, Tirapazamine Administration, Cisplatin Injection and Bleomycin Treatment. Br J Radiol (2000) 73(873):978–86. doi: 10.1259/bjr.73.873.11064652

18. Doloff JC, Khan N, Demidenko E, Swartz HM, Jounaidi Y. Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine. Curr Cancer Drug Targets (2009) 9(6):777–88. doi: 10.2174/1568009792971503

17. Wilder RB, Langmuir VK, Mendonca HL, Goris ML, Knox SJ. Local Hyperthermia and SR 4233 Enhance the Antitumor Effects of Radioimmunotherapy in Nude Mice With Human Colon Adenocarcinoma Xenografts. Cancer Res (1993) 53(13):3022–7. doi: 10.1097/00006612-199307010-00019

16. Masunaga S, Nagasawa H, Uto Y, Hori, Nagata K, Suzuki M, et al. The Usefulness of Mild Temperature Hyperthermia Combined With Continuous Tirapazamine Administration Under Reduced Dose-Rate Irradiation With Gamma-Rays. Int J Hyperthermia (2007) 23(1):29–35. doi: 10.1080/0265673061135366

15. Masunaga S, Liu Y, Sakurai Y, Tanaka H, Suzuki M, Kondo N, et al. Usefulness of Combined Treatment With Continuous Administration of Tirapazamine and Mild Temperature Hyperthermia in γ-Ray Irradiation in Terms of Local Tumor Response and Lung Metastatic Potential. Int J Hyperthermia (2012) (28):636–44. doi: 10.1080/02656736.2012.714517

14. Broekgaarden M, Weijer R, van Wijk AC, Cox RC, Egmund MR, Hoebe R, et al. Photodynamic Therapy With Liposomal Zinc Phthalocyanine and
Tirapazamine Increases Tumor Cell Death Via DNA Damage. *J Biomed Nanotechnol* (2017) 13(2):204–20. doi: 10.1166/jbn.2017.2327

64. Williamson SK, Crowley JJ, Larra PN Jr, McCoy J, Lau DH, Tucker RW, et al. Phase III Trial of Tirapazamine Plus Cisplatin in Advanced Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003. *J Clin Oncol* (2005) 23(36):9097–104. doi: 10.1200/JCO.2005.01.3771

65. Rischin D, Peters LJ, O’Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (Trog 02.02, Headstart): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. *J Clin Oncol* (2010) 28(18):2989–95. doi: 10.1200/JCO.2009.27.4449

66. Patterson LH. Rationale for the Use of Aliphatic N-oxides of Cytotoxic Anthraquinones as Prodrug DNA Binding Agents: A New Class of Bioreductive Agent. *Cancer Metastasis Rev* (1993) 12(2):119–34. doi: 10.1007/bf00689805

67. Rischin D, Hejtmadi MV, McIntyre IA, McAllear JJ, Patterson LH. AQ4N: An Alkylation-anthraquinone N-Oxide Showing Bioreductive Potential and Positive Interaction With Radiation *In Vivo*. Br J Cancer (1995) 72(1):76–81. doi: 10.1038/bjc.1995.280

68. Hejtmadi MV, McKeown SR, Friery OP, McIntyre IA, Patterson LH, Hirst DG. DNA Damage Following Combination of Radiation With the Bioreductive Drug AQ4N: Possible Selective Toxicity to Oxic and Hypoxic Tumor Cells. *Br J Cancer* (1996) 73(4):499–505. doi: 10.1038/bjc.1996.87

69. Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MC, Cole S, et al. Enhancement of Chemotherapy and Radiotherapy of Murine Tumours by AQ4N, a Bioreductive Activated Anti-Tumor Agent. *Br J Cancer* (2000) 82(12):1984–90. doi: 10.1054/bjoc.2000.1564

70. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG, et al. The Chemopotentiation of Cisplatin by the Novel Bioreductive Drug AQ4N. *Br J Cancer* (2001) 85(6):625–9. doi: 10.1054/bjoc.2001.1975

71. McCarthy HO, Yakkundi A, McElraine V, Hughes CM, Keilty G, Murray M, et al. Bioreductive GDEPT Using Cytochrome P450 3A4 in Combination With AQ4N. *Cancer Gene Ther* (2003) 10(1):40–8. doi: 10.1038/sj.cgt.7005522

72. Nishida CR, Lee M, de Montellano PR. Efficient Hypoxic Activation of the Anticancer Agent AQ4N by CYP2S1 and CYP2W1. *Mol Pharmacol* (2010) 78(3):497–502. doi: 10.1124/mol.110.056504

73. Xiao Y, Shinko R, Guengerich FP. Cytochrome P450 3A5 Is Reduced by NAPDH-cytochrome P450 Reductase. *Drug Metab Dispos* (2011) 39(6):944–6. doi: 10.1124/dmd.111.039321

74. Behnnek IG, Solaimani P, Bui P, Hankinson O. CYP2S1 Is Negatively Regulated by Corticosteroids in Human Cell Lines. *Toxicol Lett* (2012) 209(1):30–4. doi: 10.1016/j.toxlet.2011.11.020

75. Mehibel M, Singh S, Cowen RL, Williams KJ, Stratford II. Radiation Enhances the Therapeutic Effect of Banoxanthone in Hypoxic Tumour Cells With Elevated Levels of Nitric Oxide Synthase. *Oncol Rep* (2016) 35(4):1925–32. doi: 10.3892/or.2016.4555

76. Lalani AS, Alters SE, Wong A, Albertella MR, Cleland JL, Henner WD. Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer. *Cancer Res* (2007) 67(12):6264–72. doi: 10.1158/0008-5472.CAN-06-2477

77. Williams SK, Crowley JJ, Larra PN Jr, McCoy J, Lau DH, Tucker RW, et al. Phase III Trial of Paclitaxel Plus Cisplatin With or Without Tirapazamine in Advanced Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003. *J Clin Oncol* (2005) 23(36):9097–104. doi: 10.1200/JCO.2005.01.3771

78. Williamson SK, Crowley JJ, Larra PN Jr, McCoy J, Lau DH, Tucker RW, et al. Phase III Trial of Paclitaxel Plus Cisplatin With or Without Tirapazamine in Advanced Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003. *J Clin Oncol* (2005) 23(36):9097–104. doi: 10.1200/JCO.2005.01.3771

79. Williamson SK, Crowley JJ, Larra PN Jr, McCoy J, Lau DH, Tucker RW, et al. Phase III Trial of Paclitaxel Plus Cisplatin With or Without Tirapazamine in Advanced Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003. *J Clin Oncol* (2005) 23(36):9097–104. doi: 10.1200/JCO.2005.01.3771
184. Anderson RF, Li D, Hunter FW. Antagonism in Effectiveness of Evofosfamide and Doxorubicin Through Intermolecular Electron Transfer. *Free Radic Biol Med* (2017) 113:564–70. doi: 10.1016/j.freeradbiomed.2017.10.385

185. Higgins JP, Sarapa N, Kim J, Poma E. Unexpected Pharmacokinetics of Evofosfamide Observed in Phase III MAESTRO Study. *J Clin Oncol* (2018) 36(15_suppl):2568. doi: 10.1200/JCO.2018.36.15_suppl.2568

186. Hunter FW, Wang J, Patel R, Hsu HL, Hickey AJ, Hay MP, et al. Homologous Recombination Repair-Dependent Cytotoxicity of the Benzotriazine Di-N-Oxide CEN-209: Comparison With Other Hypoxia-Activated Prodrugs. *Biochem Pharmacol* (2012) 83(5):574–85. doi: 10.1016/j.bcp.2011.12.005

187. Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, et al. Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues With Improved Tissue Penetration and Hypoxic Cell Killing in Tumors. *Clin Cancer Res* (2010) 16(20):4946–57. doi: 10.1158/1078-0432.CCR-10-1439

188. Mao X, McManaway S, Jaiswal JK, Patel PB, Wilson WR, Hicks KO, et al. An Agent-Based Model for Drug-Radiation Interactions in the Tumour Microenvironment: Hypoxia-Activated Prodrug SN30000 in Multicellular Tumour Spheroids. *PLoS Comput Biol* (2018) 14(10):e1006469. doi: 10.1371/journal.pcbi.1006469

189. Mao X, McManaway S, Jaiswal JK, Hong CR, Wilson WR, Hicks KO. Schedule-Dependent Potentiation of Chemotherapy Drugs by the Hypoxia-Activated Prodrug Sn30000. *Cancer Biol Ther* (2019) 20(9):1258–69. doi: 10.1080/15384047.2019.1617570

190. Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, et al. 18f-Ef5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined With Radiation Treatment in a Non-Small Cell Lung Cancer Xenograft Model. *J Nucl Med* (2013) 54(8):1339–46. doi: 10.2967/jnumed.112.116293

191. Wang J, Foehrenbacher A, Su J, Patel R, Hay MP, Hicks KO, et al. The 2-Nitromisonidazole EFS Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 Under Hypoxia. *Clin Cancer Res* (2012) 18(6):1684–95. doi: 10.1158/1078-0432.CCR-11-2296

192. Grikovski M, Fanchon L, Pillarsetty NVK, Russell J, Humm JL. 18F-Fluoromisonidazole Predicts Evofosfamide Uptake in Pancreatic Tumor Model. *EJMNMJ Res* (2018) 8(1):53. doi: 10.1186/s13550-018-0409-1

193. Cui YL, Wang X, Li XF. (18)F-Fluoromisonidazole PET Reveals Spatial and Temporal Heterogeneity of Hypoxia in Mouse Models of Human Non-Small Cell Lung Cancer. *Future Oncol* (2015) 11(20):2841–9. doi: 10.2217/fon.15.205

194. Ljungkvist AS, Bussink J, Kaanders JH, Rijken PF, Begg AC, Raleigh JA, et al. Hypoxic Cell Turnover in Different Solid Tumor Lines. *Int J Radiat Oncol Biol Phys* (2005) 62(4):1157–68. doi: 10.1016/j.ijrobp.2005.03.049

195. Li XF, Sun X, Ma Y, Suehiro M, Zhang M, Russell J, et al. Detection of Hypoxia in Microscopic Tumors Using 131I-Labeled Iodo-Azomycin Galactopyranoside (131I-IAZGP) Digital Autoradiography. *Eur J Nucl Med Mol Imaging* (2010) 37(2):339–48. doi: 10.1007/s00259-009-1310-y

196. Li XF, Ma Y, Sun X, Humm JL, Ling CC, O’Donoghue JA. High 18F-FDG Uptake in Microscopic Peritoneal Tumors Requires Physiologic Hypoxia. *J Nucl Med* (2010) 51(4):632–8. doi: 10.2967/jnumed.109.071233

197. Huang T, Civelek AC, Zheng H, Ng CK, Duan X, Li J, et al. (18)F-Misonidazole PET Imaging of Hypoxia in Micrometastases and Macroscopic Xenografts of Human Non-Small Cell Lung Cancer: A Correlation With Autoradiography and Histological Findings. *Am J Nucl Med Mol Imaging* (2013) 3(2):142–53.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2021 Li, Zhao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**